{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:10:36Z","timestamp":1779307836828,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102532","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:39:02Z","timestamp":1772498342000},"page":"102532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Monitoring of Disease in Patients Receiving 177LU-PSMA-617 Therapy in Routine Practice"],"prefix":"10.1016","volume":"24","author":[{"given":"Narmeen S.","family":"Rashid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiwei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-8000","authenticated-orcid":false,"given":"Wanling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailey","family":"Stoltenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wolanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolivette","family":"Ritzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-078X","authenticated-orcid":false,"given":"Heather","family":"Jacene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7466-4702","authenticated-orcid":false,"given":"Praful","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102532_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2026.102532_bib0002","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clgc.2026.102532_bib0003","first-page":"15:1292","article-title":"[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): the first FDA-approved radiotherapeutical for treatment of prostate cancer","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clgc.2026.102532_bib0004","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102532_bib0005","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2026.102532_bib0006","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102532_bib0007","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/OP.22.00753","article-title":"Systemic therapy update on (177)lutetium-PSMA-617 for metastatic castration-resistant prostate cancer: ASCO guideline rapid recommendation Q and A","volume":"19","author":"Garje","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clgc.2026.102532_bib0008","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2026.102532_bib0009","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2967\/jnumed.122.264677","article-title":"(177)Lu-PSMA SPECT quantitation at 6 weeks (Dose 2) predicts short progression-free survival for patients undergoing (177)Lu-PSMA-I&T therapy","volume":"64","author":"John","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2026.102532_bib0010","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102532_bib0011","first-page":"1945","article-title":"SPECT\/CT in early response assessment of patients with metastatic castration-resistant prostate cancer receiving (177)Lu-PSMA-617","volume":"65","author":"Demirci","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2026.102532_bib0012","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2026.102532_bib0013","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/pros.24588","article-title":"Real-world analysis of metastatic prostate cancer demonstrates increased frequency of PSA-imaging discordance with visceral metastases and upfront ARAT\/docetaxel therapy","volume":"83","author":"Hara","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2026.102532_bib0014","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.eururo.2024.08.021","article-title":"Association of declining prostate-specific antigen levels with clinical outcomes in patients with metastatic castration-resistant prostate cancer receiving [(177)Lu]Lu-PSMA-617 in the phase 3 VISION trial","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102532_bib0015","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2967\/jnumed.124.267955","article-title":"Impact of posttreatment SPECT\/CT on patient management during (177)Lu-PSMA-617 radiopharmaceutical therapy","volume":"65","author":"Yadav","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2026.102532_bib0016","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2967\/jnumed.125.269640","article-title":"Prognostic value of posttherapy SPECT\/CT for overall survival in patients undergoing [(177)Lu]Lu-PSMA-617 radiopharmaceutical therapy: results from 3 clinical trials","volume":"66","author":"Kashyap","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2026.102532_bib0017","first-page":"1054","article-title":"Evidence-based clinical protocols to monitor efficacy of [(177)Lu]Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer using real-world data","volume":"66","author":"Unterrainer","year":"2025","journal-title":"J Nucl Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:45:48Z","timestamp":1779306348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000327"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102532","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring of Disease in Patients Receiving 177LU-PSMA-617 Therapy in Routine Practice","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102532"}}